Skip to main content

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Publication ,  Conference
Cloughesy, TF; Alexander, BM; Berry, DA; Colman, H; De Groot, JF; Ellingson, BM; Gordon, GB; Khasraw, M; Lassman, AB; Lee, EQ; Lim, M; Wen, PY ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Cloughesy, T. F., Alexander, B. M., Berry, D. A., Colman, H., De Groot, J. F., Ellingson, B. M., … Yung, W. K. A. (2022). GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Cloughesy, Timothy Francis, Brian Michael Alexander, Donald A. Berry, Howard Colman, John Frederick De Groot, Benjamin M. Ellingson, Gary B. Gordon, et al. “GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Cloughesy TF, Alexander BM, Berry DA, Colman H, De Groot JF, Ellingson BM, et al. GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Cloughesy, Timothy Francis, et al. “GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Cloughesy TF, Alexander BM, Berry DA, Colman H, De Groot JF, Ellingson BM, Gordon GB, Khasraw M, Lassman AB, Lee EQ, Lim M, Mellinghoff IK, Nelli A, Perry JR, Sulman EP, Tanner K, Weller M, Wen PY, Yung WKA. GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. JOURNAL OF CLINICAL ONCOLOGY. 2022.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2022

Volume

40

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences